These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 6414221)

  • 41. [Use of urokinase in acute myocardial infarction].
    Bokarev IN; Makolkin VI; Butorov VN; Terekhov VN; Kuznetsov VA
    Kardiologiia; 1988 Nov; 28(11):36-40. PubMed ID: 3068399
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Blood urokinase plasminogen activator system in chronic urticaria.
    Kasperska-Zajac A; Brzoza Z; Rogala B
    Arch Dermatol Res; 2007 Jan; 298(8):409-11. PubMed ID: 17102952
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
    Kawakami K; Takahashi A; Yoshimoto T
    No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Role of single chain pro-UK on the initiation and regulation of fibrinolysis].
    Arimura H; Kasai S; Nishida M; Suyama T
    Rinsho Byori; 1989 Apr; Spec No 81():107-17. PubMed ID: 2502639
    [No Abstract]   [Full Text] [Related]  

  • 45. Combination of high-performance affinity chromatography and specific detection of proenzyme applicable to the analysis of the fibrinolytic system of human plasma.
    Ito N; Noguchi K; Kazama M; Shimura K; Kasai K
    J Chromatogr; 1987 Jan; 386():51-6. PubMed ID: 2951390
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Low molecular weight heparin and high and low molecular weight urokinase in fibrinolysis in vivo].
    Badimón L; Villaverde CA; Vidal M; Valdecasas FG
    Arch Farmacol Toxicol; 1979 Dec; 5(3):262-4. PubMed ID: 397803
    [No Abstract]   [Full Text] [Related]  

  • 47. Purification and properties of fibrin high-affinity urokinase from human urine.
    Hayashi S; Yamada K
    Nihon Ketsueki Gakkai Zasshi; 1986 Sep; 49(6):1244-54. PubMed ID: 3811788
    [No Abstract]   [Full Text] [Related]  

  • 48. [Changes in the components of the animal fibrinolytic system induced by the action of physiological activators and enzymes of fungal origin].
    Andreenko GV; Serebriakova TN; Shimonaeva EE; Liutova LV; Karabasova MA
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (3):51-4. PubMed ID: 6342687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effect of the fibrinolytic system in experimental atheromatosis].
    Lasierra J; Díez MM; Capetillo MA; Viladés E; Gracia A; Aznar López J; Piñero J; López Campos JL; Bermudo F; Cobo R
    Sangre (Barc); 1982; 27(6):1018-29. PubMed ID: 6764034
    [No Abstract]   [Full Text] [Related]  

  • 50. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.
    Zamarron C; Lijnen HR; Van Hoef B; Collen D
    Thromb Haemost; 1984 Aug; 52(1):19-23. PubMed ID: 6495259
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Thrombolytic effect of urokinase upon various methods of administration into the body].
    Andreenko GV; Serebriakova TN; Podorol'skaia LV; Afanasenko GA; Liaginskiĭ AV; Raevskaia AK
    Vopr Med Khim; 1992; 38(1):44-6. PubMed ID: 1441294
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Kinetics of the reaction between urokinase and an inhibitor of fibrinolysis from placental tissue.
    Christensen U; Holmberg L; Bladh B; Astedt B
    Thromb Haemost; 1982 Aug; 48(1):24-6. PubMed ID: 6813991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fibrinolytic therapy urokinase for myocardial infarction.
    Nakano M
    Angiology; 1983 Oct; 34(10):654-73. PubMed ID: 6625222
    [No Abstract]   [Full Text] [Related]  

  • 54. Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model.
    Burke SE; Lubbers NL; Nelson RA; Henkin J
    Thromb Haemost; 1997 May; 77(5):1025-30. PubMed ID: 9184422
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunochemical studies of high and low molecular forms of urokinase.
    Sumi H; Toki N; Maehara S; Kosugi T; Akazawa K; Matsuo O; Mihara H
    Acta Haematol; 1982; 67(4):263-7. PubMed ID: 6810625
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The inhibition by plasma of urokinase and tissue activator-induced fibrinolysis in pregnancy and the puerperium.
    Walker JE; Gow L; Campbell DM; Ogston D
    Thromb Haemost; 1983 Feb; 49(1):21-3. PubMed ID: 6221434
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Threshold phenomena in blood fibrinolysis.
    Matsuo O; Mihara H
    Thromb Res; 1977 May; 10(5):753-8. PubMed ID: 882961
    [No Abstract]   [Full Text] [Related]  

  • 59. [Pharmacological studies of intracoronary administered urokinase].
    Ishiguro J; Mizota M; Sato M; Funato H; Nakajima H; Yamazaki M; Kayamoto M
    Nihon Yakurigaku Zasshi; 1986 Sep; 88(3):215-22. PubMed ID: 3792956
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasma urokinase levels measured by chromogenic assay after infusions of tissue culture or urinary source material.
    Barlow GH; Marder VJ
    Thromb Res; 1980 May 1-15; 18(3-4):431-7. PubMed ID: 6998041
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.